Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).
AMD is the leading cause of blindness in the developed world. Its prevalence is increasing dramatically as the population ages and it is estimated that, by 2020, there will be about 200 million people worldwide with the condition. In the UK alone, there are over 500,000 people with late stage AMD.
AMD is currently treated by injections of sight-saving drugs into the eye which must be administered by medical professionals. Scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Microbiology and Infection, have invented a method of delivering these otherwise-injected drug as eye drops.
Laboratory research, published last year in Investigative Ophthalmology & Visual Science (IOVS), showed that these eye drops have a similar therapeutic effect as the injected drug in rats. Now the Birmingham scientists have taken their research one step further by investigating the effect of the eye drops in the larger eyes of rabbits and pigs, which are more similar to human eyes.
This latest study, also published in IOVS, demonstrates that the eye drops can deliver a therapeutically effective amount of the drugs to the retina of the larger mammalian eye.
The technology behind the eye drops is a cell-penetrating peptide that can deliver the drug to the retina (the back of the eye). The scientists’ pending patents for the eye drops are now owned by US-based company, Macregen Inc, and a team of Birmingham researchers is working with the company to develop a novel range of therapies for AMD and other eye diseases.
The combined team is now expediting proof of concept studies to confirm the validity of the therapeutic approach. Clinical trials will be imminent once these studies are completed, and could start as early as spring 2019.
Dr de Cogan said: “For several years, our team has focused on the challenge of delivering drugs to the back of the eye.
“From the outset, we realised that delivering drugs through eye drops would mean that patients can administer their treatment themselves, and this would be less costly, save time for patients and healthcare providers, and reduce the potential complications that can arise from injections.
“Now we have shown that the eye drops work in the larger mammalian eye, and we welcome the commercial investment and expertise from Macregen so we can deliver a structured research and development programme that should bring concrete benefits to people with AMD and eye diseases.”
Professor Robert Scott, Consultant Ophthalmologist and Honorary Professor of Ophthalmology at University of Birmingham, commented: “Cell-penetrating peptides will drive the next generation of treatment for people with AMD.
“They will be transformative for patients who currently have to organise their lives around monthly clinic visits for uncomfortable intraocular injections, who will in the future have the convenience of self-administering their medical treatment.”
Keith Roizman, Founder, Executive Chairman, and Chief Technology Officer of Macregen, said: “Macregen and the company’s prospective strategic partners and licensees are expected to make significant investments in laboratory proof of concept studies, the subsequent research and development programmes and clinical trials.
“We will also pursue the necessary and required regulatory programmes to make these eye drops available to patients.”
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- Health: High levels of air pollution can increase your risk of macular degenerationon January 25, 2021 at 3:57 pm
Researchers from the UK studied data on 15,954 people - each of whom was aged 40-69 at the start of the study and initially reported no vision issues.
- Common Cause of Vision Loss Linked to Air Pollution — What to Knowon January 25, 2021 at 3:49 pm
U.K. researchers found that air pollution may be significantly associated with developing age-related macular degeneration (AMD), which can lead to vision loss.
- Air pollution exposure could increase risk of irreversible sight loss, study suggestson January 25, 2021 at 3:31 pm
Exposure to air pollution could increase the risk of developing a form of irreversible sight loss in older age, researchers have claimed following a large-scale observational study. The long-term ...
- Air pollution linked to heightened risk of progressive and irreversible sight loss (AMD)on January 25, 2021 at 3:31 pm
Air pollution is linked to a heightened risk of progressive and irreversible sight loss, known as age related macular degeneration, or AMD for short, reveals a large long term study, published online ...
- Roche’s Macular Degeneration Drug Hits Mark in Two Phase III Trialson January 25, 2021 at 10:22 am
Roche announced topline data from two identical Phase III trials (TENAYA and LUCERNE) of faricimab in neovascular or “wet” age-related macular degeneration (nAMD), with both studies hitting their ...
- Roche eyes FDA filing after bispecific matches Eylea againon January 25, 2021 at 4:54 am
Roche’s bispecific faricimab has matched Regeneron’s Eylea in another pair of phase 3 clinical trials. The top-line results suggest the VEGFxAng2 bispecific antibody faricimab performs as well as ...
- Genentech's Faricimab Meets Primary Endpoint In Late-stage Studies On Neovascular AMDon January 24, 2021 at 10:34 pm
Genentech, a member of the Roche Group (RHHBY), said that its investigational bispecific antibody, faricimab, met primary endpoint in two global phase III studies. The two identically designed ...
- Genentech's Faricimab Meets Primary Endpoint...on January 24, 2021 at 10:00 pm
Faricimab given at intervals of up to every 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks, potentially reducing ...
- Eyedaptic Augmented Reality Visual Aid Granted Patent to Further Aid Those With Macular Degeneration and Low Visionon January 21, 2021 at 10:07 pm
Eyedaptic, Inc., a natural vision software company, announced today they were recently granted their first out of nine pending patents. Additionally, Eyedaptic launched an Equity Crowdfunding Campaign ...
via Bing News